InflaRx NV (IFRX)
1.44
+0.04
(+2.86%)
USD |
NASDAQ |
May 16, 16:00
1.44
0.00 (0.00%)
After-Hours: 20:00
InflaRx Research and Development Expense (Quarterly): 7.931M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.931M |
| December 31, 2023 | 8.688M |
| September 30, 2023 | 7.954M |
| June 30, 2023 | 11.91M |
| March 31, 2023 | 15.82M |
| December 31, 2022 | 8.524M |
| September 30, 2022 | 7.593M |
| June 30, 2022 | 11.91M |
| March 31, 2022 | 11.75M |
| December 31, 2021 | 11.59M |
| September 30, 2021 | 11.04M |
| June 30, 2021 | 13.62M |
| March 31, 2021 | 5.913M |
| December 31, 2020 | 6.894M |
| September 30, 2020 | 6.135M |
| June 30, 2020 | 8.102M |
| Date | Value |
|---|---|
| March 31, 2020 | 8.054M |
| December 31, 2019 | 12.16M |
| September 30, 2019 | 14.91M |
| June 30, 2019 | 14.04M |
| March 31, 2019 | 8.741M |
| December 31, 2018 | 10.35M |
| September 30, 2018 | 6.338M |
| June 30, 2018 | 6.007M |
| March 31, 2018 | 6.725M |
| December 31, 2017 | 7.427M |
| September 30, 2017 | 3.064M |
| June 30, 2017 | 3.412M |
| March 31, 2017 | 2.558M |
| December 31, 2016 | 3.023M |
| September 30, 2016 | 1.182M |
| June 30, 2016 | 0.6474M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.913M
Minimum
Mar 2021
15.82M
Maximum
Mar 2023
10.23M
Average
9.862M
Median
Research and Development Expense (Quarterly) Benchmarks
| Affimed NV | 20.09M |
| MorphoSys AG | 86.49M |
| BioNTech SE | 551.24M |
| Immatics NV | 35.83M |
| CureVac NV | 35.93M |